新京报贝壳财经讯1月6日，爱朋医疗（300753）公告，公司股票交易价格于2026年1月5日、2026年1月6 日连续两个交易日内收盘价格涨幅偏离值累计超过30%。公司前期披露的信息不存在需要更正、补充之 处；公司未发现近期公共传媒报道了可能或已经对本公司股票交易价格产生较大影响的未公开重大信 息；公司近期经营情况正常，内外部经营环境未发生重大变化；公司、控股股东及实际控制人不存在关 于本公司的应披露而未披露的重大事项，或处于筹划阶段的重大事项；公司控股股东、实际控制人在股 票异常波动期间不存在买卖公司股票情形。 ...

新京报贝壳财经讯1月6日，南华生物发布公告称，公司于2025年8月12日披露拟现金收购程泽能等合计 持有的慧泽医药51%股权，交易完成后慧泽医药将成控股子公司。根据初步测算，本次交易预计构成重 大资产重组，不构成关联交易，不涉及发行股份，也不会导致控制权变更。截至公告披露日，针对慧泽 医药的审计、评估等工作仍在进行，相关方就核心条款谈判，尚未签署正式收购协议，交易实施存在不 确定性。 ...

Core Viewpoint - The company, Nongfa Seed Industry, has received approval from the China Securities Regulatory Commission (CSRC) for a stock issuance to specific investors, which is a significant step for its capital raising efforts [1] Group 1 - The company announced that it has received the CSRC's approval for its application to issue stocks to specific investors [1] - The approval is documented in the CSRC's notice, which is identified as document number 2966 [1] - The stock issuance must be carried out strictly according to the submitted application documents and issuance plan to the Shanghai Stock Exchange [1] Group 2 - The approval is valid for 12 months from the date of registration consent [1]

Core Viewpoint - The stock price of Aerospace Electronics has experienced a significant increase, with a cumulative rise of 123.23% since November 27, 2025, which is substantially higher than the 25.71% increase in the military industry and the 5.38% increase in the Shanghai Composite Index during the same period. However, the company's fundamentals have not changed significantly, indicating potential market overreaction and irrational speculation [1]. Summary by Category - **Stock Performance** - The stock price of Aerospace Electronics has deviated by a cumulative increase of 20% over three consecutive trading days (December 31, 2025, January 5, 2026, and January 6, 2026) [1]. - The cumulative increase of 123.23% since November 27, 2025, is significantly higher than the military industry’s increase of 25.71% and the Shanghai Composite Index’s increase of 5.38% [1]. - **Market Sentiment** - The short-term stock price increase is considered to be excessively high compared to the industry and index performance, suggesting a potential overreaction in market sentiment [1]. - There is an indication of irrational speculation surrounding the stock, as the company's fundamentals have not undergone any major changes [1].

Core Viewpoint - The company, Xinbang Pharmaceutical, has received a prosecution notice from the People's Court of Kaiyang County, Guizhou Province, indicating that it may face criminal charges for unit bribery under Article 393 of the Criminal Law of the People's Republic of China [1] Summary by Relevant Categories Legal Issues - The prosecution notice suggests that the company is accused of violating the law regarding bribery, which could lead to significant legal consequences [1] Financial Impact - The announcement indicates that this major legal issue may have a negative impact on the company's profits [1]

新京报贝壳财经讯 1月6日，嘉美包装公告，公司股票自2025年12月17日至2026年1月6日期间价格涨幅 为230.48%，期间多次触及股票交易异常波动情形，公司股票短期内价格涨幅较大，已背离公司基本 面，为维护投资者利益，公司将就股票交易波动情况进行停牌核查。经公司向深圳证券交易所申请，公 司股票自2026年1月7日(星期三)开市起停牌，预计停牌时间不超过3个交易日。公司提醒广大投资者注 意二级市场交易风险。 编辑 王进雨 ...

Core Viewpoint - The investigation reveals that the product "Kangaroo Jack Baby Plant Extract Nasal Balm" is being falsely marketed as a solution for adenoid facial features and various nasal discomforts in children, leading to regulatory scrutiny [1][2]. Regulatory Actions - The Shenzhen Market Supervision Administration has initiated an investigation into the misleading advertising practices of the "Kangaroo Jack Baby Products Flagship Store" [4]. - The live stream has removed content suggesting improvements to adenoid facial features, but continues to imply benefits for nasal discomfort and allergic rhinitis [5]. Product Misrepresentation - The product is classified as a children's cosmetic, and its claimed effects do not align with its registered information, which states its purpose is for moisturizing and soothing the facial area, not for nasal issues [3]. - Legal experts indicate that the promotion of the product as having medical benefits violates multiple regulations, including the Cosmetics Supervision and Administration Regulations and the Advertising Law [3]. Advertising Practices - The live stream previously featured images and phrases that reinforced the product's supposed effectiveness for adenoid facial features, but has since altered its messaging while still hinting at benefits for nasal discomfort [2][5]. - The product's packaging and promotional materials have been criticized for misleading consumers regarding its intended use and benefits, particularly in relation to its application in the nasal cavity [3][9]. Consumer Misleading Claims - The term "baby gold standard filing" used in promotions is misleading, as it suggests a special certification that does not exist; the "small gold shield" merely indicates the product is a children's cosmetic [10]. - The National Medical Products Administration has clarified that the "small gold shield" is not a quality certification but a distinguishing mark for children's cosmetics [10].

2025年，工业和信息化部等七部门联合发布了《关于推动脑机接口产业创新发展的实施意见》，设定了 2027年和2030年的清晰发展目标。同时，国家医保局为脑机接口项目单独立项收费，解决了支付端的关 键问题，行业标准也已出台，共同推动产业进入落地阶段。《中共中央关于制定国民经济和社会发展第 十五个五年规划的建议》中，脑机接口被明确列为需要前瞻布局的未来产业之一，旨在推动其成为新的 经济增长点。西南证券研报指出，结合七部委发布的《关于推动脑机接口产业创新发展的实施意见》可 以看出，脑机接口的应用将超越医疗康复，向工业制造、生活消费、教育娱乐等多领域拓展，最终目标 是让技术进步成果实现普惠共享。 资本市场的强烈反应，不仅源于脑机接口技术突破的利好，更基于对脑机接口行业广阔市场前景的预 期。Precedence Research及锐观咨询数据显示，2024年全球脑机接口市场规模约26亿美元，国内约32亿 元；预计到2034年全球脑机接口市场规模将增长至约124亿美元；而赛迪顾问预测，2024至2028年我国 脑机接口市场规模年均增速约20%，显著快于传统装备制造等成熟赛道。 开源证券研报分析认为，脑机接口行业正处于政策 ...

Core Insights - Baidu Encyclopedia has launched new features including "Dynamic Encyclopedia" and "AI Knowledge Graph" based on AI technology [1] - The total number of entries in Baidu Encyclopedia has surpassed 30 million, with over 8.03 million cumulative contributors [1]

Core Viewpoint - Chow Sang Sang has initiated a price increase for certain gold jewelry products, making it the first jewelry brand to publicly adjust prices in 2026, with increases ranging from 200 to 1500 yuan [1][2]. Price Adjustments - As of January 6, 2026, Chow Sang Sang's gold jewelry prices have been updated, with most products seeing a price increase of approximately 5% to 15% [1][2]. - Specific examples include a black zodiac gold bead priced at 3740 yuan, up from 3380 yuan, reflecting a 10.7% increase [1]. - The price of 1 gram of gold jewelry is reported at 1387 yuan, a rise of about 0.8% from the previous trading day, and a 42 yuan increase since January 1, 2026 [2]. Industry Trends - The jewelry industry is experiencing a concentrated price adjustment period, with brands like Chow Sang Sang, Chow Tai Fook, and others raising prices due to rising gold prices and material costs [2][3]. - In 2025, Chow Sang Sang had previously raised prices by about 10% during September and October, with individual product price increases ranging from 100 to 500 yuan [2]. - The overall trend indicates that the jewelry sector is in a sensitive pricing cycle, with brands needing to balance cost recovery and consumer demand amidst high gold prices [3]. Financial Performance - Chow Sang Sang's gross profit margin increased by 5.2 percentage points to 33.5% in the first half of 2025, primarily due to improved margins from gold products [3]. - Gold jewelry accounted for 82% of total sales in mainland China, with priced gold jewelry making up 34% of that total [3]. - The company has been closing stores, with a net reduction of about 10% in store count expected by the end of 2026 [3].